Pàgina inicial > Resultats de la cerca: Stein, A.S.
  Consells de cerca
Cerca avançada
Cerca col·leccions:
Ordena'ls per: Mostrar els resultats: Format de visualizació:
Resultats globals: 3 registres trobats en 0.03 segons.
Articles, 3 registres trobats
Articles 3 registres trobats  
1.
7 p, 820.3 KB Blinatumomab for Acute Lymphoblastic Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation / Stein, A. S. (Gehr Family Center for Leukemia Research. City of Hope) ; Kantarjian, H. (The University of Texas M.D. Anderson Cancer Center) ; Gökbuget, N. (Department of Medicine II. Goethe University) ; Bargou, R. C. (Comprehensive Cancer Center Mainfranken. University Hospital Würzburg) ; Litzow, Mark R (Mayo Clinic) ; Rambaldi, Alessandro (Department of Oncology and Hemato-Oncology. University of Milan and Azienda Pope John XXIII Hospital) ; Ribera, Jose-Maria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Zhang, A. (Amgen Inc.) ; Zimmerman, Z. (Amgen Inc.) ; Zugmaier, Gerhard (Amgen Research Munich) ; Topp, M. S. (Medical Clinic and Polyclinic II. University Hospital Würzburg) ; Universitat Autònoma de Barcelona
Patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) following allogeneic hematopoietic stem cell transplantation (alloHSCT) have a poor prognosis, and alternative therapies are needed for this patient population. [...]
2019 - 10.1016/j.bbmt.2019.04.010
Biology of blood and marrow transplantation, Vol. 25 Núm. 8 (august 2019) , p. 1498-1504  
Registre complet - Creative Commons
2.
6 p, 186.9 KB Long-term survival of patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab / Topp, Max S. (Universitätsklinikum Würzburg) ; Gökbuget, Nicola (Goethe University) ; Zugmaier, Gerhard (Amgen GmbH) ; Stein, Anthony S. (Gehr Family Center for Leukemia Research. City of Hope) ; Dombret, Hervé (Saint Louis Hospital. University of Paris) ; Chen, Yuqi (Amgen. Inc) ; Ribera, Jose-Maria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Bargou, Ralf C. (Comprehensive Cancer Center Mainfranken. University Hospital Würzburg) ; Horst, Heinz-August (Universitätsklinikum Schleswig-Holstein (Alemanya)) ; Kantarjian, H. M. (The University of Texas MD Anderson Cancer Center) ; Universitat Autònoma de Barcelona
Background: Blinatumomab is a CD19 BiTE (bispecific T-cell engager) immuno-oncology therapy that mediates the lysis of cells expressing CD19. Methods: A pooled analysis of long-term follow-up data from 2 phase 2 studies that evaluated blinatumomab in heavily pretreated adults with Philadelphia chromosome-negative, relapsed/refractory B-cell precursor acute lymphoblastic leukemia was conducted. [...]
2021 - 10.1002/cncr.33298
Cancer, Vol. 127 Núm. 4 (15 2021) , p. 554-559  
Registre complet - Creative Commons
3.
7 p, 171.0 KB Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia / Rambaldi, Alessandro (Department of Oncology and Hematology. University of Milan) ; Ribera, Jose-Maria (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Kantarjian, H. M. (Department of Leukemia. University of Texas MD Anderson Cancer Center) ; Dombret, Hervé (Department of Hematology. Hopital Saint-Louis. Paris Diderot University) ; Ottmann, O. G. (Division of Cancer and Genetics. School of Medicine. Cardiff University) ; Stein, A. S. (Gehr Family Center for Leukemia Research. City of Hope) ; Tuglus, C. A. (Amgen. Inc) ; Zhao, X. (Amgen. Inc) ; Kim, C. (Amgen. Inc) ; Martinelli, Giovanni (Scientific Institute of Romagna for the Study and Treatment of Cancer) ; Universitat Autònoma de Barcelona
Background: A single-arm, phase 2 trial demonstrated the efficacy and safety of blinatumomab, a bispecific T-cell-engaging antibody construct, in patients with relapsed/refractory (r/r) Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL), a rare hematologic malignancy with limited treatment options. [...]
2020 - 10.1002/cncr.32558
Cancer, Vol. 126 Núm. 2 (15 2020) , p. 304-310  
Registre complet - Creative Commons

Vegeu també: autors amb noms similars
2 Stein, A. S.
1 Stein, Airton
1 Stein, Airton T.
2 Stein, Alejandra
1 Stein, Anthony
1 Stein, Anthony S.
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.
Dipòsit Digital de Documents de la UAB :: Cerca :: Lliura :: Personalitza :: Ajuda
Powered by Invenio v1.1.6
Mantingut per ddd.bib@uab.cat  :: Metadades subjectes a:
Col·laborem